Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT03680794

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Led by CHU de Reims · Updated on 2026-04-30

120

Participants Needed

1

Research Sites

504 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test. The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

CONDITIONS

Official Title

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Over 18 years old
  • Have social security affiliation
  • Willing to participate in this study
Not Eligible

You will not qualify if you...

  • Received anti-VEGF therapy, corticosteroids, or immunosuppressive agents within the past 3 months
  • History of vitreoretinal surgery, ocular tumor, severe eye trauma, severe intraocular or periocular infection, inflammation, or radiation
  • Severe allergy to fluorescein sodium used in angiography
  • History of systemic anti-VEGF treatment
  • History of inflammatory or autoimmune disease
  • Active extraocular inflammation or infection within 4 weeks before surgery
  • C-reactive protein level greater than 10 mg/mL during surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chu Reims

Reims, France, 51092

Actively Recruiting

Loading map...

Research Team

C

Carl ARNDT

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here